Home
About
Publications Trends
Recent Publications
Expert Search
Archive
humoral hypercalcemia of malignancy (hhm)
What Causes HHM?
The primary cause of HHM is the
secretion of parathyroid hormone-related protein (PTHrP)
by the tumor cells. PTHrP mimics the action of parathyroid hormone, leading to increased bone resorption and renal tubular calcium reabsorption, which results in elevated blood calcium levels. Other factors that can contribute include increased production of
Vitamin D analogs
by lymphomas and the direct
osteolytic activity of bone metastases
.
Frequently asked queries:
What is HHM?
What Causes HHM?
What are the Symptoms of HHM?
How is HHM Diagnosed?
What are the Treatment Options for HHM?
What is the Prognosis for Patients with HHM?
How Can HHM be Prevented?
How can avoiding risky behaviors reduce cancer risk?
How Do Normal Cells Become Cancerous?
What are the Key Areas of Training?
What Support is Available for Cancer Patients Experiencing Menopausal Symptoms?
Who is a Principal Investigator?
How is CDKN1C implicated in cancer prognosis and therapy?
What are Copyrights?
What Role Does Compliance Play?
Why is Patient Support Crucial in Cancer Care?
Why is Growth Factor Support Important in Cancer Treatment?
What research is ongoing in the field of NBS and cancer?
What is Cerebrospinal Fluid (CSF)?
What Cancers Can Be Treated with Cell-Based Therapies?
Top Searches
Brain Tumor
Breast cancer
cancer
Cancer Genomics
Chemotherapy
hepatocellular carcinoma
Lung Cancer
Nanotechnology
Non-Hodgkin’s Lymphoma
Radiation-Induced Malignancies
Follow Us
Facebook
Linkedin
Youtube
Instagram
Partnered Content Networks
Relevant Topics
4D Segmentation
Alopecia
Atlas-based Segmentation
Automated Segmentation
B-cell malignancies
biomarkers
Brain Tumor
Brain Tumor Segmentation
Breast cancer
cancer
Cancer Genome Atlas
Cancer genomics
Cancer treatment
CAR T-cell therapy
Carcinogenesis
cell adhesion
cell migration
chemotherapy
Chromatin remodeling genes
Chronic inflammation
CIAbimatoprost
Co-morbidity
Combination therapy
Copy number variations
cytokine release syndrome
Deep Learning
Diagnosis challenges
diffuse large B-cell lymphoma
DNA damage
docetaxel-cyclophosphamide
Drug delivery
epirubicin-cyclophosphamide
extracellular matrix
Fibrosis
Genetic alteration
Glioblastoma
Gold nanoparticles
Hepatocellular carcinoma
High Tumor
image-guided radiotherapy
Imaging Techniques
Immunosuppression
Immunotherapy
Integrative genomics
integrin inhibitors
Integrins
intensity-modulated radiation therapy
Keratinocyte
Lipid-based nanoparticles
liver cancer
long-term cancer risks
Lung cancer
Machine Learning
Magnetic Resonance Imaging
metastasis
methyltransferase
MRI
Multi-modal Imaging
Multidisciplinary care
Mutual exclusivity analysis
Nanoparticles
Nanotechnology
neoadjuvant radiotherapy
neurotoxicity
Next-generation sequencing
nnovative Biomarkers
Non-Hodgkin’s lymphoma
Novel Biomarkers for Brain Tumors
Novel Chemotherapy
Oncogenic transcription factors
oncological diseases
paclitaxel
Personalized medicine
Photobiomodulation therapy
Polymeric nanoparticles
portal vein tumor thrombus
Probabilistic Models
proton therapy
Radiation-induced malignancies
radiotherapy
refractory lymphoma
relapsed lymphoma
Risk factors
secondary cancer prevention
secondary cancers
Silver nanoparticles
stereotactic body radiation therapy
Targeted therapy
Tolerability
transarterial chemoembolization
Tuberculosis
tumor microenvironment
tumor progression
Voltage-gated sodium channels
Subscribe to our Newsletter
Stay updated with our latest news and offers related to Cancer.
Subscribe